PLK1

(redirected from polo-like kinase 1)

PLK1

A gene on chromosome 16p12.2 that encodes a member of the CDC5/Polo subfamily of serine/threonine protein kinases, which performs several key functions during the M phase of the cell cycle—e.g., regulating centrosome maturation and spindle assembly, removing cohesins from chromosome arms, inactivating anaphase-promoting complex/cyclosome (APC/C) inhibitors, and regulating mitotic exit and cytokinesis.
 
Molecular pathology
Defects in PLK1 are associated with gastric, thyroid and B-cell malignancies, with increased expression linked to a worse prognosis.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Trovagene is developing onvansertib, a first-in-class, third-generation, oral and highly-selective Polo-like Kinase 1 inhibitor that targets the key master regulator of tumor cell division, for the treatment of leukemias, lymphomas and solid tumor cancers.
According to the company's CEO and chair Thomas Adams, more investors are becoming aware of its multi-faceted clinical development programme of Onvansertib, a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor.
As part of the agreement, PoC Capital LLC will fund the clinical development of Onvansertib, Trovagene's first-in-class, 3rd generation oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor in a Phase 1b/2 clinical trial in patients with metastatic Colorectal Cancer (mCRC), the second leading cause of cancer mortality in the US.
PCM-075 is an oral, highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine Polo-like Kinase 1 (PLK1) enzyme, which appears to be over expressed in several different hematologic malignancies and solid tumor cancers.
Acting on the knowledge that the gene polo-like kinase 1 (PLK1) can become overexpressed during ADT and that its overexpression can also stimulate androgen synthesis, Xiaoqui Liu and colleagues tested the effects of administering the PLK1-inhibitor B12536 with low-dose metformin in prostate cancer cells.
In particular, Aurora-A in association with the G2 induced Bora protein phosphorylates the PLK1 (polo-like kinase 1).
MAP9 is phosphorylated by the mitotic kinases Aurora A (AURKA) [20] and Polo-like kinase 1 (PLK1) [21] to ensure bipolar spindle assembly and centrosome integrity.
Sanhaji et al., "Long-term downregulation of polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1/CIP1," Cell Cycle, vol.
Sidhu et al., "Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma," Leukemia Research, vol.
Xiaoqi Liu, an assistant professor of Biochemistry, has claimed that an overabundance of the polo-like kinase 1 (Plk1) molecule during cell growth, as well as a shortage of the p53 molecule, could lead to tumour formation.
(NASDAQ: TROV) has developed a method for predicting response to treatment by measuring the ability of Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, to inhibit PLK1 in patients with Acute Myeloid Leukemia, the company said.
Onvansertib is a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 Inhibitor that is being evaluated in an ongoing Phase 1b/2 clinical trial at nine sites in the U.S.